FDA Approves Novel Non-Opioid Treatment for Moderate to …
6 days ago · Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults....
JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain in adults. (1) Recommended starting JOURNAVX oral dose is 100 mg. Take the starting dose on...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
Jan 30, 2025 · BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to …
FDA Approves Journavx (suzetrigine), a First-in-Class Treatment …
FDA Approves Journavx BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
Journavx: Uses, Dosage, Side Effects, Warnings - Drugs.com
3 days ago · Journavx FDA approval was received on January 30, 2025, for treating moderate to severe acute pain in adults. This approval was based on positive results from Phase 3 clinical trials (VX21-548-101 and VX21-548-102), which showed that it effectively reduced acute pain for 48 hours after surgery.
FDA approves first new type of pain medication in 25 years
6 days ago · It will be sold under the brand name Journavx. A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. ... acting director of the FDA ...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
6 days ago · BOSTON–(BUSINESS WIRE)–Jan. 30, 2025– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an ...
FDA Approves Journavx, First New Non-Opioid Pain Pill in Decades
6 days ago · FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin. The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the Associated Press reported.
FDA Approves Journavx Drug to Treat Pain Without Addiction …
6 days ago · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat ...
FDA approves Journavx, first novel painkiller in more than 20 …
Jan 30, 2025 · The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
- Some results have been removed